FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Merck | Gardasil | cervical cancer

Study examines cost-effectiveness of Gardasil

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

A new study in the New England Journal of Medicine questions the cost-effectiveness of Gardasil in older women, saying that the payback is reduced by their increased exposure to the virus that causes cervical cancer. But the team of researchers from Harvard School of Public Health also confirmed that the vaccine is cost-effective among pre-adolescent girls because of their reduced exposure to the virus. Merck, which makes the vaccine and markets it around the world, quickly disputed the study, saying that its own economic models indicate that the vaccine provides a real payback when used for women.

The discussion over cost-effectiveness in the older age bracket is critical for Merck, which wants to expand the use of the cervical cancer vaccine. That expanded use is key to the company's efforts to gain more revenue from the vaccine. It's also an important discussion for GlaxoSmithKline, which has been commercializing Cervarix in various markets and working to gain an FDA approval.

--read the report in the Wall Street Journal

Related Articles:
Will Gardasil special help Merck?
Merck marketing role in Vioxx study
Gardasil side effects prompt CDC study
CDC details side effects reported on Gardasil
Gardasil: Some good news for Merck


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Comments (1) | Post a comment
More stories about Vaccine   Merck   Gardasil   cervical cancer  

Comments

I guess the study published earlier this week about Merck seeding studies on Vioxx is irrelevant here.......?????!!!!

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.